Kazuhiro Ito is an expert in Pulmonology at Imperial College London (United Kingdom). As of October 2026, ScienceLeadR ranks Kazuhiro Ito in the top 1% of experts worldwide for Lung Diseases, Obstructive. Kazuhiro Ito has authored 282 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 827 (community average: 125). How the SLR is computed.

LeadR Profile

Kazuhiro Ito Imperial College London United Kingdom
827 ScienceLeadR Reputation 827
Network Map

Pulmonology

Subspecialties: Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026

Source: PubMed

Imperial College London

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
A utility of air-liquid interface cultured airway epithelium for the development of antiviral agents: translation beyond biology.
PMID 42518853 — respiratory syncytial viruses, air, cell biology, viruses, epithelium, antiviral agents
Front Cell Infect Microbiol20261
Role of ITIH4 in Modulating YAP/TAZ-Mediated Apoptosis of Type II Alveolar Epithelium during Acute Respiratory Distress Syndrome.
PMID 41735691 — cells, lung, acute lung injury, pharmacy, caspase 3, caspases, research, therapeutics, apoptosis, respiratory distress syndrome, epithelium
Pharm Res20260
Harnessing innate immunity to prevent viral exacerbations: current strategies and future directions for chronic inflammatory lung disease management.
PMID 41538064 — disease management, lung, rhinovirus, influenza, human, immunity, asthma, lung diseases, immunity, innate
Expert Rev Respir Med20260
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
PMID 40686671 — kidney diseases, quality of life, health care costs, kidney, quality-adjusted life years, therapeutics
EClinicalMedicine20250
Can inhaled antifungals provide a viable solution for treatment-refractory pulmonary fungal infections?
PMID 40613353 — voriconazole, aerosols, inhalation, solutions, lung diseases, fungal, mycoses, therapeutics, infections
Expert Rev Anti Infect Ther20250

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 2
Phase 1/Phase 2 1
Phase 3 1
Phase 4 1

By status:

Completed 4
Withdrawn 1

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map